GT Biopharma (GTBP) Gross Margin (2010 - 2015)

GT Biopharma (GTBP) posted quarterly Gross Margin of 100.0% for Q2 2015, little changed quarter-over-quarter from 100.0% in Q1 2015.

GT Biopharma (GTBP) Gross Margin (2010 - 2015) Analysis & Trends

GT Biopharma (GTBP) has reported Gross Margin for 5 consecutive years, with 100.0% the latest figure, recorded in Q2 2015.

In Q2 2015, Gross Margin changed N/A year-over-year to 100.0%; the TTM figure through Mar 2016 stood at 100.0% (up 75714.0% YoY), while the FY2015 annual figure was 100.0%, up 8571.0% from the prior year.
Gross Margin was little changed at 100.0% in Q2 2015 per GTBP's latest filing, from 100.0% in the prior quarter.
Across five years, Gross Margin topped out at 100.0% in Q4 2011 and bottomed at 1400.0% in Q2 2011.
Historically, Gross Margin has averaged 135.85% across 4 years, with a median of 47.46% in 2013.
On a YoY basis, Gross Margin climbed as much as 150000 bps in 2012 and fell as far as 22846 bps in 2012.
GT Biopharma's Gross Margin stood at 100.0% in 2011, then slumped by 228 bps to 128.46% in 2012, then surged by 117 bps to 21.59% in 2013, then jumped by 363 bps to 100.0% in 2015.
Business Quant data shows GTBP's Gross Margin at 100.0% in Q2 2015, 100.0% in Q1 2015, and 21.59% in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	91.59%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	90.43%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	76.90%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	63.27%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	84.20%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	GT Biopharma	8.64 Mn	8.64 Mn	-	-

Download Data